Drugs / STT-5058
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04419688 | May 2020 → Dec 2022 | hypertriglyceridemia | Staten Biotechnology BV | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STT-5058 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04419688 ↗ |
| Modality | Monoclonal antibody | “Monoclonal Antibody STT-5058” NCT04419688 ↗ |
| Route | Intravenous | “Intravenously Administered STT-5058” NCT04419688 ↗ |
| Target | APOC3 | “A First in Human Study of STT-5058, an Antibody That Binds ApoC3” NCT04419688 ↗ |